Department of Thrombosis and Hemostasis, Leiden University Medical Center
Karina Meijer
University of Groningen, Department of Hematology, University Medical Center Groningen
Marieke Kruip
Department of Hematology, Erasmus University Medical Center, Rotterdam
Britta Laros-van Gorkom
Department of Hematology, Radboud university medical center, Sophia Children’s Hospital Rotterdam
Marjolein Peters
Department of Pediatric Hematology, Academic Medical Center, Amsterdam
Saskia de Wildt
Intensive Care and Department of Pediatric Intensive Care, Erasmus University Medical Center - Sophia Children’s Hospital Rotterdam;Department of Pharmacology, Radboud university medical center, The Netherlands
Frank Leebeek
Department of Hematology, Erasmus University Medical Center, Rotterdam
Marjon Cnossen
Department of Pediatric Hematology, Erasmus University Medical Center - Sophia Children’s Hospital Rotterdam
Ron Mathôt
Hospital Pharmacy-Clinical Pharmacology, Academic Medical Center Amsterdam, The Netherlands
The role of pharmacokinetic-guided dosing of factor concentrates in hemophilia is currently a subject of debate and focuses on long-term prophylactic treatment. Few data are available on its impact in the perioperative period. In this study, a population pharmacokinetic model for currently registered factor VIII concentrates was developed for severe and moderate adult and pediatric hemophilia A patients (FVIII levels
